Cell therapy for the treatment of metabolic liver disease: An update on the umbilical cord derived stem cells candidates

Open Tissue Engineering and Regenerative Medicine Journal

Volumn 4, Issue SPEC. ISSUE 1, 2011, Pages 48-53

  Scheers, I ^a   Lombard, C ^a   Najimi, M ^a   Sokal, E M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Hepatocyte differentiation; Liver regeneration; Umbilical cord stem cells

Indexed keywords

CELL DIFFERENTIATION; CELL FUNCTION; HEPATOCYTE TRANSPLANTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER DISEASE; LIVER FIBROSIS; MESENCHYMAL STEM CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE; ANIMAL CELL; CELL PROLIFERATION; CELL THERAPY; CELL TYPE; HUMAN CELL; IMMUNOREACTIVITY; LIVER CELL; LIVER TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLIC LIVER DISEASE; RODENT; STEM CELL; UMBILICAL CORD BLOOD; UMBILICAL CORD DERIVED STEM CELL;

RODENTIA;

EID: 84855798289     PISSN: None     EISSN: 18750435     Source Type: Journal    
DOI: 10.2174/1875043501104010048     Document Type: Review

References (60)

1. Sterling RK, Fisher RA. Liver transplantation. Living donor, hepatocyte, and xenotransplantation. Clin Liv Dis 2001; 5: 431-60
2. Fox IJ, Chowdhury JR, Kaufman SS, Goertzen TC, Chowdhury NR. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 1998; 338: 1422-6.
3. Smets F, Najimi M, Sokal EM. Cell transplantation in the treatment of liver disease. Pediatr Transplant 2008; 12: 6-13.
4. Stephenne X, Najimi M, Sibille C, Nassogne MC, Smets F, Sokal EM. Sustained engraftment and tissue enzyme activity after liver cell transplantation for arginosuccinate lyase deficiency. Gastroenterology 2006; 130: 1317-23.
5. Lee KD, Kuo TK, Whang-Peng J, et al. In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology 2004; 40: 1275-84.
6. Hong SH, Gang EJ, Jeong JA, et al. In vitro differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocyte-like cells. Biochem Biophys Res Commun 2005; 330: 1153-61.
7. Seo MJ, Suh SY, Bae YC, Jung JS. Differentiation of human adipose stromal cells into hepatic lineage in vitro and in vivo. Biochem Biophys Res Commun 2005; 328: 258-64.
8. Espejel S, Roll GR, Mc Laughlin KJ, et al. Induced pluripotent stem cell-derived hepatocytes have the functional and proliferative capabilities needed for liver regeneration in mice. J Clin Invest 2010; 120: 3120-6.
9. Chien CC, Yen BL, Lee FK, et al. In vitro differentiation of human placenta-derived multipotent cells and into hepatocyte-like cells. Stem Cells 2006; 24: 1759-68.
10. Campard D, Lysy PH, Najimi M, Sokal EM. Native umbilical cord matrix stem cells express hepatic markers and differentiate into hepatocyte-like cells. Gastroenterology 2008; 134: 833-48.
11. Najimi M, Khuu ND, Lysy PA, et al. Adult-derived human liver mesenchymal-like cells as a potential progenitor reservoir of hepatocytes? Cell Transplant 2007; 16: 717-28.
12. Zheng YB, Gao ZL, Xie C, et al. Characterization and hepatogenic differentiation of mesenchymal stem cells from human amniotic fluid and human bone marrow: a comparative study. Cell Biol Int 2008; 32: 1439-48.
13. Lavon N, Benvenisty N. Study of hepatocyte differentiation using embryonic stem cells: Prometheus revisited? J Cell Biochem 2005; 96: 1193-202.
14. Lysy PA, Smets F, Sibille C, Najimi M, Sokal EM. Human skin fibroblasts: from mesodermal to hepatocyte-like differentiation. Hepatology 2007; 46: 1574-85.
15. Stadtfeld M, Graf T. Assessing the role of hematopoietic plasticity for endothelial and hepatocyte development by non-invasive lineage tracing. Development 2005; 132: 203-13.
16. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315-7.
17. Lysy PA, Campard D, Smets F, Najimi M, Sokal EM. Stem cells for liver tissue repair: current knowledge and perspectives. World J Gastroenterol 2008; 14: 864-75.
18. Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007; 262: 509-25.
19. Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003; 33: 919-26.
20. Wang HS, Hung SC, Peng ST, et al. Mesenchymal stem cells in the Wharton's Jelly of the human umbilical cord. Stem Cells 2004; 22: 1330-7.
21. Karahuseyinoglu S, Cinar O, Kilic E, et al. Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells 2007; 25: 319-31.
22. Troyer DL, Weiss ML. Concise review: Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells 2008; 26: 591-9.
23. Zhang YN, Lie PC, Wei X. Differentiation of mesenchymal stromal cells derived from umbilical cord Wharton's jelly into hepatocytelike cells. Cytotherapy 2009; 11: 548-58.
24. Zhao Q, Ren H, Li X, et al. Differentiation of human umbilical cord mesenchymal stromal cells into low immunogenic hepatocyte-like cells. Cytotherapy 2009; 11: 414-26.
25. Zhao R, Duncan SA. Embryonic development of the liver. Hepatology 2005; 41: 956-67.
26. Zaret KS. Regulatory phases of early liver development: paradigms of organogenesis. Nat Rev Genet 2002; 3: 499-511.
27. Lemaigre FP. Mechanisms of liver development: concepts for understanding liver disorders and design of novel therapies. Gastroenterology 2009; 137: 62-79.
28. Schmelzer E, Wauthier E, Reid LM. The phenotypes of pluripotent human hepatic progenitors. Stem Cells 2006; 24: 1852-8.
29. Turner WS, Schmelzer E, McClelland R, Wauthier E, Chen W, Reid LM. Human hepatoblast phenotype maintained by hyaluronan hydrogels. J Biomed Mater Res B Appl Biomater 2007; 82: 156-68.
30. Nekanti U, Dastidar S, Venugopal P, Totey S, Ta M. Increased proliferation and analysis of differential gene expression in human Wharton's jelly-derived mesenchymal stromal cells under hypoxia. Int J Biol Sci 2010; 6: 499-512.
31. Roelandt P, Pauwelyn KA, Sancho-Bru P, et al. Human embryonic and rat adult stem cells with primitive endoderm-like phenotype can be fated to definitive endoderm, and finally hepatocyte-like cells. Plos One 2010; 5: e12101.
32. La Rocca G, Anzalone R, Corrao S, et al. Isolation and characterization of Oct-4+/HLA-G+ mesenchymal stem cells from human umbilical cord matrix: differentiation potential and detection of new markers. Histochem Cell Biol 2009; 131: 267-82.
33. Desmet VJ, Van Eyken P, Sciot R. Cytokeratins for probing cell lineage relationships in developing liver. Hepatology 1990; 12: 1249-51.
34. Stosiek P, Kasper M, Karsten U. Expression of cytokeratin 19 during human liver organogenesis. Liver 1990; 10: 59-63.
35. Zhang L, Theise N, Chua M, Reid LM. The stem cell niche of human livers: symmetry between development and regeneration. Hepatology 2008; 48: 1598-607.
36. Lazaro CA, Croager EJ, Mitchell C, et al. Establishment, characterization, and long-term maintenance of cultures of human fetal hepatocytes. Hepatology 2003; 38: 1095-106.
37. Conconi MT, Burra P, Di Liddo R, et al. CD105(+) cells from Wharton's jelly show in vitro and in vivo myogenic differentiative potential. Int J Mol Med 2006; 18: 1089-96.
38. Weiss ML, Medicetty S, Bledsoe AR, et al. Human umbilical cord matrix stem cells: preliminary characterization and effect of transplantation in a rodent model of Parkinson's disease. Stem Cells 2006; 24: 781-92.
39. Lin SZ, Chang YJ, Liu JW, et al. Transplantation of human Wharton's Jelly-derived stem cells alleviates chemically induced liver fibrosis in rats. Cell Transplant 2010; 19: 1451-63.
40. Inada M, Follenzi A, Cheng K, et al. Phenotype reversion in fetal human liver epithelial cells identifies the role of an intermediate meso-endodermal stage before hepatic maturation. J Cell Sci 2008; 121: 1002-13.
41. Hengstler JG, Brulport M, Schormann W, et al. Generation of human hepatocytes by stem cell technology: definition of the hepatocyte. Expert Opin Drug Metab Toxicol 2005; 1: 61-74.
42. [Scheers I, Lombard C, Paganelli M, et al. Umbilical cord matrix stem cells maintain a stable immunophenotype and do not undergo transformation during long-term in vitro culture. In Press.
43. Jung J, Zheng M, Goldfarb M, Zaret KS. Initiation of mammalian liver development from endoderm by fibroblast growth factors. Science 1999; 284: 1998-2003.
44. Zaret KS. Hepatocyte differentiation: from the endoderm and beyond. Curr Opin Genet Dev 2001; 11: 568-74.
45. Kamiya A, Kinoshita T, Ito Y, et al. Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer. EMBO J 1999; 18: 2127-36.
46. Sancho-Bru P, Najimi M, Caruso M, et al. Stem and progenitor cells for liver repopulation: can we standardize the process from bench to bedside? Gut 2009; 58: 594-603.
47. Zaret KS. Regulatory phases of early liver development: paradigms of organogenesis. Nat Rev Genet 2002; 3: 499-511.
48. [Maerckx C, Campard D, Tondreau T, et al. Hepato-biliary profile of candidate liver progenitor cells isolated from healthy rat liver. World J Gastroenterol. [In Press].
49. Gupta S, Gorla GR, Irani AN. Hepatocyte transplantation: emerging insights into mechanisms of liver repopulation and their relevance to potential therapies. J Hepatol 1999; 30: 162-70.
50. Grompe M, Laconi E, Shafritz DA. Principles of therapeutic liver repopulation. Sem Liv Dis 1999; 19: 7-14.
51. Weiss ML, Anderson C, Medicetty S, et al. Immune properties of human umbilical cord Wharton's Jelly-derived cells. Stem cells 2008; 26: 2865-74.
52. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-69.
53. Sakaida I, Terai S, Yamamoto N, et al. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004; 40:1304-11.
54. Yan Y, Xu W, Qian H, et al. Mesenchymal stem cells from human umbilical cords ameliorate mouse hepatic injury in vivo. Liver Int 2009; 29: 356-65.
55. Tsai PC, Fu TW, Chen YM, et al. The therapeutic potential of human umbilical mesenchymal stem cells from Wharton's Jelly in the treatment of rat liver fibrosis. Liver Transplant 2009; 15: 484-95.
56. Mias C, Lairez O, Trouche E, et al. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells 2009; 27: 2734-43.
57. Rabani V, Shahsavani M, Gharavi M, Piryaei A, Azhdari Z, Baharvand H. Mesenchymal stem cell infusion therapy in a carbon tetrachloride-induced liver fibrosis model affects matrix metalloproteinase expression. Cell Biol Int 2010; 34: 601-5.
58. Carvalho RL, Quintanilha LF, Dias JV, et al. Bone marrow multipotent mesenchymal stromal cells do not reduce fibrosis or improve function in a rat model of severe chronic liver injury. Stem Cells 2008; 26: 1307-14.
59. di Bonzo LV, Ferrero I, Cravanzola C, et al. Human mesenchymal stem cells as a two-edge sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut 2008; 57: 223-31.
60. Nussler A, Konig S, Ott M, et al. Present status and perspectives of cell-based therapies for liver diseases. J Hepatol 2006; 45: 144-59.